Free Trial
NASDAQ:GOSS

Gossamer Bio Q2 2025 Earnings Report

Gossamer Bio logo
$2.59 +0.12 (+4.86%)
Closing price 09/2/2025 04:00 PM Eastern
Extended Trading
$2.59 +0.00 (+0.04%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Gossamer Bio Revenue Results

Actual Revenue
$11.49 million
Expected Revenue
$4.12 million
Beat/Miss
Beat by +$7.37 million
YoY Revenue Growth
N/A

Gossamer Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Gossamer Bio's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Monday, November 3, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gossamer Bio Earnings Headlines

Gossamer Bio to Present at Upcoming Investor Conferences
Gossamer Bio: A Critical Year Ahead
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
See More Gossamer Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email.

About Gossamer Bio

Gossamer Bio (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

View Gossamer Bio Profile

More Earnings Resources from MarketBeat